Assessing the Burden of Adverse Events in a Head-to-Head Trial of Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia (CLL)
Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 7050-7052
10.1182/blood-2022-157060